NEW YORK (TheStreet) -- Response Genetics  (RGDX) surged 25% to $1.50 at 10:26 a.m. on Thursday after the molecular diagnostic test developer announced contracts with six new provider networks, which increases its total membership to more than 174 million U.S. members.

The contracts span 10 states and include Blue Cross Blue Shield contracts in Arizona, Delaware, Iowa, Pennsylvania, South Dakota and West Virginia; an Independent Physician Association that covers two states in the North West region; and a Commercial Health Plan that covers two states in the North East region.

Thanks to the deals, Response Genetics is now in-network with thirteen Blue Cross Blue Shield health plans, which increases the number of Blue Cross Blue Shield subscribers with direct access to Response Genetics to approximately 23 million.

Must Read:Warren Buffett's 10 Favorite Growth Stocks

TheStreet Recommends

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title

RGDX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.